drugset
drugset / Trial / NCT02972658

A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

NCT02972658 ↗

Phase 3 Terminated 421 enrolled AstraZeneca Eli Lilly and Company · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is an extension of study I8D-MC-AZES (NCT02245737), the AMARANTH study. The purpose of this study is to evaluate the effectiveness of the study drug lanabecestat in participants with early Alzheimer's disease dementia at the time of entry into study I8D-MC-AZES.

Timeline

Start
2017-03-15
Primary completion
2018-10-02
Completion
2018-10-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Lanabecestat Small molecule 20 mg Oral
Subject Lanabecestat Small molecule 50 mg Oral

Indications

Alzheimer disease